Kidney Cancer Drugs Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Kidney Cancer Drugs Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Report Description
Renal cell carcinoma (RCC) is one of the most common types of kidney cancer in adults. At the advanced progression stage of kidney cancer, where removal of the cancerous cells is vital; surgical removal of kidney are performed to get cure from the disease. This treatment method was later replaced by laparoscopic removal of tumor-affected area. Medicines are generally prescribed to cure tumors at advanced stage of disease progression.
In recent times, owing to increasing drug resistivity key players are shifting its focus in developing combination drug therapy for kidney cancer medication. Increasing trend of combination drug therapy in near future, will help in overcoming potential hazards of drug resistivity and offer treatment option in renal cell carcinoma.
In addition, key players are engaged in developing cancer immunotherapy drugs to fight cancer and improve immune system. For instance, F. Hoffmann-La Roche Ltd. is working on Tecentriq (atezolizumab, anti-PDL1, RG7446, MPDL3280A) — an engineered monoclonal antibody, that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion— which will be used as adjuvant treatment in renal cell carcinoma treatment. Tecentriq is currently in phase III stage, which is expected to be launched in the market by the end of 2021.
Market Dynamics
Key drug manufacturers in the kidney cancer drugs market are adopting in-organic growth strategies to collaborate with other drug manufacturers and develop renal cell carcinoma drugs.
For instance, in March 2021, Eisai Co., Ltd. and Merck & Co., Inc. entered into strategic collaboration agreement for co-development and co-commercialization of LENVIMA (lenvatinib mesylate), an orally available tyrosine kinase inhibitor, for renal cell carcinoma. Under the terms of agreement, Eisai and Merck will develop and commercialize LENVIMA jointly, both as monotherapy and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab).
Moreover, in June 2016, Eisai Co., Ltd. entered into a partnership with Novartis Pharmaceuticals to collaborate on commercial and medical affairs activities on a combination treatment for advanced renal cell carcinoma. According to the agreement, sales teams from both pharmaceutical companies will promote the availability of Levinima (lenvatinib mesylate) to healthcare professionals in the U.S.
In December 2013, Cancer Research UK and Cancer Research Technology, signed an agreement with AstraZeneca to take AZD2098, an experimental drug originally designed for asthma, into a clinical trial to treat kidney cancer.
Key features of the study:
This report provides in-depth analysis of kidney cancer drugs market, its market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021, as the base year.
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategy adopted by key players
It profiles key players in the global kidney cancer drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies.
Key companies covered as a part of this study include, Pfizer Inc., Novartis International AG, Genentech, Inc., Active Biotech AB, Amgen Inc., Bayer AG, Cipla Limited, Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Eisai Co., Ltd. and Exelixis, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future type upgradation, market expansion, and marketing tactics
The global kidney cancer drugs market report caters to various stakeholders in this industry including investors, researchers, kidney cancer drug manufacturers, new entrants, and financial analysts.
Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the kidney cancer drugs market.
Detailed Segmentation:
Global Kidney Cancer Drugs Market, By Therapy:
Targeted Therapy
Immunotherapy
Chemotherapy
Global Kidney Cancer Drugs Market, By Pharmacological Class:
Angiogenesis Inhibitors
mTOR Inhibitors
Cytokines
Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
Global Kidney Cancer Drugs Market, By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Global Kidney Cancer Drugs Market, By Geography:
North America
By Country:
U.S.
Canada
By Therapy:
Targeted Therapy
Immunotherapy
Chemotherapy
By Pharmacological Class:
Angiogenesis Inhibitors
mTOR Inhibitors
Cytokines
Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Therapy:
Targeted Therapy
Immunotherapy
Chemotherapy
By Pharmacological Class:
Angiogenesis Inhibitors
mTOR Inhibitors
Cytokines
Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Asia Pacific
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
By Therapy:
Targeted Therapy
Immunotherapy
Chemotherapy
By Pharmacological Class:
Angiogenesis Inhibitors
mTOR Inhibitors
Cytokines
Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Therapy:
Targeted Therapy
Immunotherapy
Chemotherapy
By Pharmacological Class:
Angiogenesis Inhibitors
mTOR Inhibitors
Cytokines
Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Therapy:
Targeted Therapy
Immunotherapy
Chemotherapy
By Pharmacological Class:
Angiogenesis Inhibitors
mTOR Inhibitors
Cytokines
Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Africa
By Country:
North Africa
Central Africa
South Africa
By Therapy:
Targeted Therapy
Immunotherapy
Chemotherapy
By Pharmacological Class:
Angiogenesis Inhibitors
mTOR Inhibitors
Cytokines
Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Company Profiles
Pfizer Inc.*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Novartis International AG
Genentech, Inc.
Active Biotech AB
Amgen Inc.
Bayer AG
Cipla Limited
Hoffmann-La Roche AG
Bristol-Myers Squibb Company
Eisai Co., Ltd.
Exelixis, Inc.
“*” marked represents similar segmentation in other categories in the respective section.